Kairos Pharma, Ltd.
KAPAAMEXHealthcare● Active
$0.45
$-0.00(-0.89%)
Market Cap$9549395
P/E Ratio—
52W High$2.11
52W Low$0.43
Kairos Pharma, Ltd. (KAPA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KAPA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.08
Est. -$0.07 · -14.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS
KAPA reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $4.26B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$4.26B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.09 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.07 | -$0.08 | -14.3% | — | — | — |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$0.02 | -$0.07 | -275.3% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.10 | -$0.07 | +30.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.06 | -$0.08 | -33.3% | — | — | — |
| ▼ Q2 FY2025 | Apr 15, 2025 | -$0.05 | -$0.08 | -60.0% | — | — | — |
| ▼ Q1 FY2025 | Feb 26, 2025 | -$0.06 | -$0.09 | -43.8% | — | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.02 | -$0.10 | -400.0% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.09
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$0.08
EPS Est.
-$0.07
EPS Surpr.
-14.3%
Revenue
—
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$0.07
EPS Est.
-$0.02
EPS Surpr.
-275.3%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.10
EPS Surpr.
+30.0%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.08
EPS Est.
-$0.06
EPS Surpr.
-33.3%
Revenue
—
Q2 FY2025
Apr 15, 2025Miss
EPS Actual
-$0.08
EPS Est.
-$0.05
EPS Surpr.
-60.0%
Revenue
—
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
-$0.09
EPS Est.
-$0.06
EPS Surpr.
-43.8%
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.10
EPS Est.
-$0.02
EPS Surpr.
-400.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q3 FY2028 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q2 FY2028 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q1 FY2028 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q4 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q3 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -14.3% | $0.49 | $0.46 | -4.33% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -275.3% | $0.55 | $0.56 | +1.64% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +30.0% | $0.79 | $0.83 | +4.80% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -33.3% | $0.99 | $1.12 | +13.71% |
| ▼ Q2 FY2025 | Apr 15, 2025 | -60.0% | $0.95 | $0.98 | +3.36% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -43.8% | $1.14 | $1.24 | +8.77% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -400.0% | $2.21 | $2.06 | -6.79% |
| — Q2 FY2024 | Jun 30, 2024 | — | No price data | $2.60 | — |
Q2 FY2026-4.33%
Report Date
May 13, 2026
EPS Beat/Miss
-14.3%
Price Before
$0.49
Price After
$0.46
Q1 FY2026+1.64%
Report Date
Mar 31, 2026
EPS Beat/Miss
-275.3%
Price Before
$0.55
Price After
$0.56
Q4 FY2025+4.80%
Report Date
Nov 14, 2025
EPS Beat/Miss
+30.0%
Price Before
$0.79
Price After
$0.83
Q3 FY2025+13.71%
Report Date
Aug 12, 2025
EPS Beat/Miss
-33.3%
Price Before
$0.99
Price After
$1.12
Q2 FY2025+3.36%
Report Date
Apr 15, 2025
EPS Beat/Miss
-60.0%
Price Before
$0.95
Price After
$0.98
Q1 FY2025+8.77%
Report Date
Feb 26, 2025
EPS Beat/Miss
-43.8%
Price Before
$1.14
Price After
$1.24
Q4 FY2024-6.79%
Report Date
Nov 14, 2024
EPS Beat/Miss
-400.0%
Price Before
$2.21
Price After
$2.06
Q2 FY2024—
Report Date
Jun 30, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$2.60
Avg Beat Reaction+4.80%
Avg Miss Reaction+2.73%
Beat Rate1 / 8 quarters
Largest Move+13.71% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KAPA ends December
Kairos Pharma, Ltd. (KAPA) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.08 — missing the analyst consensus of $-0.07 by -14.3%. The next KAPA earnings date is expected around September 1, 2026.
Each quarter, investors track KAPA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KAPA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KAPA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KAPA earnings · 5 questionsKairos Pharma, Ltd.'s next earnings report is expected around September 1, 2026. KAPA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KAPA historically reports after market close (AMC).
KAPA earnings datewhen is KAPA earningsKAPA next earnings datewhen does KAPA report earningsKAPA earnings calendar
▸ Source: FMP · Kairos Pharma, Ltd. SEC filings · US GAAP · Kairos Pharma, Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026